Although activating KRAS mutations occur frequently in cancer, targeting this oncogene has proved difficult. Three groups have now identified pathways that have not been previously linked to KRAS ...

Representative KRAS-directed combination therapy trials are shown that have completed accrual, are currently open or are awaiting activation. † Clinicaltrials.gov identifier. RAF, PI3K and the ...

In 5–10 years, data from the second generation of clinical trials targeting KRAS downstream signaling pathways will have emerged, incorporating novel therapeutic approaches such as the ...

Background: "The KRAS pathway plays a crucial role in cell biology by regulating cell growth, proliferation, differentiation, and survival," said Xie. "While KRAS signaling is tightly regulated in ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...